流感：预防与治疗概述
Influenza: overview on prevention and therapy.
作者信息
Robson Christopher, Baskar Sai Rupa, Booy Robert, Ferguson Patricia E, Gilroy Nicole, Kok Jen, Sandaradura Indy, Dwyer Dominic
机构信息
Department of Infectious Diseases, Westmead Hospital, Sydney.
National Centre for Immunisation Research and Surveillance, Kids Research Institute at The Children's Hospital at Westmead, Sydney.
出版信息
Aust Prescr. 2019 Apr;42(2):51-55. doi: 10.18773/austprescr.2019.013. Epub 2019 Apr 1.
Abstract
Quadrivalent influenza vaccination is recommended annually for adults and children aged six months to 64 years High-dose or adjuvanted trivalent vaccines are recommended annually for people 65 years and over If started early enough, neuraminidase inhibitors reduce symptom duration by approximately one day. Treatment should be considered in patients with severe disease requiring hospitalisation or who are at risk of complications Chemoprophylaxis is not a substitute for vaccination but can be considered in high-risk individuals with an inadequate or ineffective vaccination status
摘要
建议6个月至64岁的成人和儿童每年接种四价流感疫苗。建议65岁及以上的人群每年接种高剂量或含佐剂的三价疫苗。如果尽早开始，神经氨酸酶抑制剂可将症状持续时间缩短约一天。对于需要住院治疗的重症患者或有并发症风险的患者，应考虑进行治疗。化学预防不能替代疫苗接种，但对于疫苗接种不足或无效的高危个体可考虑采用。
相似文献
1
Influenza: overview on prevention and therapy.流感：预防与治疗概述
Aust Prescr. 2019 Apr;42(2):51-55. doi: 10.18773/austprescr.2019.013. Epub 2019 Apr 1.
2
Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial.在英国（ComFluCOV）成年人中同时接种 COVID-19 疫苗（ChAdOx1 或 BNT162b2）和季节性流感疫苗的安全性和免疫原性：一项多中心、随机、对照、4 期临床试验。
Lancet. 2021 Dec 18;398(10318):2277-2287. doi: 10.1016/S0140-6736(21)02329-1. Epub 2021 Nov 11.
3
Comparative efficacy and safety of vaccines to prevent seasonal influenza: A systematic review and network meta-analysis.预防季节性流感疫苗的比较疗效与安全性：一项系统评价和网状Meta分析
EClinicalMedicine. 2022 Mar 25;46:101331. doi: 10.1016/j.eclinm.2022.101331. eCollection 2022 Apr.
4
Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022-23 Influenza Season.疫苗预防和控制季节性流感：免疫实践咨询委员会的建议-美国，2022-23 流感季节。
MMWR Recomm Rep. 2022 Aug 26;71(1):1-28. doi: 10.15585/mmwr.rr7101a1.
5
[Technical guidelines for seasonal influenza vaccination in China (2023-2024)].《中国季节性流感疫苗接种技术指南（2023—2024年）》
Zhonghua Liu Xing Bing Xue Za Zhi. 2023 Oct 10;44(10):1507-1530. doi: 10.3760/cma.j.cn112338-20230908-00139.
6
[Technical guidelines for seasonal influenza vaccination in China (2022-2023)].《中国季节性流感疫苗接种技术指南（2022—2023年）》
Zhonghua Yu Fang Yi Xue Za Zhi. 2022 Oct 6;56(10):1356-1386. doi: 10.3760/cma.j.cn112150-20220825-00840.
7
[Technical guidelines for seasonal influenza vaccination in China (2022-2023)].《中国季节性流感疫苗接种技术指南（2022—2023年）》
Zhonghua Liu Xing Bing Xue Za Zhi. 2022 Oct 10;43(10):1515-1544. doi: 10.3760/cma.j.cn112338-20220825-00734.
8
[Technical guidelines for seasonal influenza vaccination in China (2021-2022)].《中国季节性流感疫苗接种技术指南（2021—2022年）》
Zhonghua Liu Xing Bing Xue Za Zhi. 2021 Oct 10;42(10):1722-1749. doi: 10.3760/cma.j.cn112338-20210913-00732.
9
[Technical guidelines for seasonal influenza vaccination in China (2020-2021)].《中国季节性流感疫苗接种技术指南（2020—2021年）》
Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Oct 10;41(10):1555-1576. doi: 10.3760/cma.j.cn112338-20200904-01126.
10
Antiviral drugs in influenza: an adjunct to vaccination in some situations.流感抗病毒药物：在某些情况下作为疫苗接种的辅助手段。
Prescrire Int. 2006 Feb;15(81):21-30.
引用本文的文献
1
Vaccine adjuvants: current status, research and development, licensing, and future opportunities.疫苗佐剂：现状、研究与开发、许可和未来机遇。
J Mater Chem B. 2024 May 1;12(17):4118-4137. doi: 10.1039/d3tb02861e.
2
Late diagnosis of respiratory syncytial virus and influenza co-infection during coronavirus disease 2019 pandemic: a case report.2019 冠状病毒病大流行期间呼吸道合胞病毒和流感合并感染的迟诊：病例报告。
J Med Case Rep. 2023 Oct 21;17(1):437. doi: 10.1186/s13256-023-04187-3.
3
A Tale of Three Recent Pandemics: Influenza, HIV and SARS-CoV-2.近期三大疫情之故事：流感、艾滋病毒与新型冠状病毒2019
Front Microbiol. 2022 Jun 2;13:889643. doi: 10.3389/fmicb.2022.889643. eCollection 2022.
4
Geroprotective and senoremediative strategies to reduce the comorbidity, infection rates, severity, and lethality in gerophilic and gerolavic infections.减少嗜老年菌和嗜老年病毒感染中的合并症、感染率、严重程度及致死率的老年保护和衰老修复策略。
Aging (Albany NY). 2020 Mar 31;12(8):6492-6510. doi: 10.18632/aging.102988.
5
Managing the overlap of asthma and chronic obstructive pulmonary disease.哮喘与慢性阻塞性肺疾病重叠的管理
Aust Prescr. 2020 Feb;43(1):7-11. doi: 10.18773/austprescr.2020.002. Epub 2020 Feb 3.
6
Peramivir for influenza.帕拉米韦用于治疗流感。
Aust Prescr. 2019 Aug;42(4):143. doi: 10.18773/austprescr.2019.047. Epub 2019 Jun 17.
7
Flu vaccination when travelling between countries.
Aust Prescr. 2019 Aug;42(4):122. doi: 10.18773/austprescr.2019.049. Epub 2019 Aug 1.
本文引用的文献
1
A Phase III randomised trial of the immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in adult and elderly subjects, assessing both anti-haemagglutinin and virus neutralisation antibody responses.一项关于成人和老年受试者中四价与三价灭活亚单位流感疫苗免疫原性和安全性的 III 期随机试验，评估了抗血凝素和病毒中和抗体反应。
Vaccine. 2018 Sep 25;36(40):6030-6038. doi: 10.1016/j.vaccine.2018.04.043. Epub 2018 Apr 27.
2
A Double-Blind, Randomized Trial of High-Dose vs Standard-Dose Influenza Vaccine in Adult Solid-Organ Transplant Recipients.成人实体器官移植受者中高剂量与标准剂量流感疫苗的双盲、随机试验。
Clin Infect Dis. 2018 May 17;66(11):1698-1704. doi: 10.1093/cid/cix1082.
3
Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial.奥司他韦、金刚烷胺和利巴韦林联合抗病毒疗法与奥司他韦单药疗法治疗流感的疗效比较：一项多中心、双盲、随机2期试验
Lancet Infect Dis. 2017 Dec;17(12):1255-1265. doi: 10.1016/S1473-3099(17)30476-0. Epub 2017 Sep 22.
4
Comparative effectiveness of high-dose versus standard-dose influenza vaccination on numbers of US nursing home residents admitted to hospital: a cluster-randomised trial.高剂量与标准剂量流感疫苗接种对美国养老院居民住院人数的影响比较：一项整群随机试验。
Lancet Respir Med. 2017 Sep;5(9):738-746. doi: 10.1016/S2213-2600(17)30235-7. Epub 2017 Jul 20.
5
Comparison of Side Effects of the 2015-2016 High-Dose, Inactivated, Trivalent Influenza Vaccine and Standard Dose, Inactivated, Trivalent Influenza Vaccine in Adults ≥65 Years.2015 - 2016年高剂量、灭活、三价流感疫苗与标准剂量、灭活、三价流感疫苗对≥65岁成年人副作用的比较。
Open Forum Infect Dis. 2017 Jan 12;4(1):ofx001. doi: 10.1093/ofid/ofx001. eCollection 2017 Winter.
6
Comparative Effectiveness of High-Dose Versus Standard-Dose Influenza Vaccines Among US Medicare Beneficiaries in Preventing Postinfluenza Deaths During 2012-2013 and 2013-2014.2012 - 2013年及2013 - 2014年期间，高剂量与标准剂量流感疫苗在美国医疗保险受益人群中预防流感后死亡的比较效果
J Infect Dis. 2017 Feb 15;215(4):510-517. doi: 10.1093/infdis/jiw641.
7
Immunogenicity and safety of a quadrivalent inactivated influenza vaccine compared with two trivalent inactivated influenza vaccines containing alternate B strains in adults: A phase 3, randomized noninferiority study.成人中四价灭活流感疫苗与两种含不同B株的三价灭活流感疫苗相比的免疫原性和安全性：一项3期随机非劣效性研究。
Vaccine. 2017 Apr 4;35(15):1856-1864. doi: 10.1016/j.vaccine.2017.02.066. Epub 2017 Mar 13.
8
Influenza antivirals currently in late-phase clinical trial.目前处于后期临床试验阶段的流感抗病毒药物。
Influenza Other Respir Viruses. 2017 May;11(3):240-246. doi: 10.1111/irv.12446. Epub 2017 Feb 28.
9
Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial.静脉注射扎那米韦或口服奥司他韦治疗流感住院患者：一项国际性、随机、双盲、双模拟、3 期临床试验。
Lancet Respir Med. 2017 Feb;5(2):135-146. doi: 10.1016/S2213-2600(16)30435-0. Epub 2017 Jan 14.
10
Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: A systematic review and meta-analysis.MF59佐剂季节性流感疫苗在老年人中的有效性：一项系统评价和荟萃分析。
Vaccine. 2017 Jan 23;35(4):513-520. doi: 10.1016/j.vaccine.2016.12.011. Epub 2016 Dec 23.
Zotero 插件